肾癌组织中CD44v6和P16蛋白的表达及临床意义

目的　探讨评估肾细胞癌预后因素的指标。方法　应用免疫组化方法 ,对 6 0例肾癌组织进行CD4 4v6和P16蛋白检测。结果　在肾癌细胞中CD4 4v6和P16蛋白表达阳性率分别为 6 6 .7%和 5 1.7%。肾细胞癌分级、分期和淋巴结转移与CD4 4v6高表达和P16低表达相关 (P <0 .0 5 )。CD4 4v6表达与P16表达呈负相关 (r=- 0 .4 3,P <0 .0 5 )。结论　CD4 4v6和P16表达对判断肾细胞癌恶性程度及预测淋巴结转移有一定的参考价值     

CD44v6和E-上皮钙黏附素在前列腺癌组织中的表达与癌转移的关系

目的 :探讨CD4 4v6和E 上皮钙黏附素 (E cadherin ,ED)表达与前列腺癌转移的关系。　方法 :应用免疫组化方法 ,对 4 5例前列腺癌组织进行了CD4 4v6和ED蛋白检测。　结果 :在前列腺癌中CD4 4v6和ED表达阳性率为77.8%和 4 8.9%。CD4 4v6高表达和ED低表达与前列腺癌分化程度、临床病理分期和转移密切相关 (P <0 .0 5 )。CD4 4v6表达与ED表达呈负相关 (r=0 .5 8,P <0 .0 0 5 )。　结论 :CD4 4v6和ED蛋白表达可作为辅助临床判断前列腺癌生物学行为和预测预后的参考指标     

原发性乳腺癌PCNA、P53表达及临床意义

目的　探讨增殖细胞核抗原 (PCNA)、P5 3表达与原发性乳腺癌临床病理学参数和预后的关系。方法　运用免疫组织化学方法对 48例原发性乳腺癌组织切片中PCNA、P5 3的表达进行检测。结果　PCNA表达和原发灶大小、腋淋巴结转移、TNM分期、组织学分级相关 (P <0 .0 5 )。P5 3表达和腋淋巴结转移、TNM分期、病理学类型和组织学分级相关 (P <0 .0 5 )。PCNA高表达者P5 3阳性率高 ,差别显著 (P <0 .0 5 )。在单因素分析中 ,PCNA、P5 3、腋淋巴结、原发灶大小、TNM分期对预后的判断有统计学意义 (P <0 .0 5 )。COX比例风险回归模型的分析表明 ,腋淋巴结和PCNA是影响乳腺癌预后的独立因素 (P <0 .0 5 )。结论　PCNA和P5 3免疫组化染色可以作为判断乳腺癌患者预后的有价值的指标。     

钙粘附分子和CD44v6表达与膀胱移行细胞癌生物学特性的关系

目的　探讨钙粘附分子E cadherin(E CD)和CD44v6的表达与膀胱移行细胞癌发生及发展的关系。　方法　应用S P免疫组化染色法检测 96例膀胱移行细胞癌中E CD和CD44v6的表达。　结果　E CD和CD44v6阳性率分别为 :Ⅰ级 86 .7% (2 6 / 30 ) ,80 .0 % (2 4/ 30 ) ;Ⅱ级 5 2 .8% (19/ 36 ) ,6 9.4% (2 5 / 36 ) ;Ⅲ级 2 6 .7% (8/ 30 ) ,33 .3 % (10 / 30 )。E CD和CD44v6阳性率与膀胱移行细胞癌分级、分期 ,复发及生存率显著相关 (P <0 .0 1)。　结论　E CD和CD44v6阳性表达率与膀胱移行细胞癌生物学特性密切相关。     

胃癌PCNA和CD44V6表达的相互关系及其临床意义的研究

目的　研究增殖细胞核抗原 (PCNA)和CD44V6表达与胃癌侵袭转移及预后的关系 ,探讨胃癌组织PCNA和CD44V6表达的相互关系。方法　采用SP免疫组化染色方法 ,检测 90例胃癌组织PCNA和CD44V6的表达情况。结果　胃癌组织PCNA标记指数 (LI)为6 3 83 %± 17 16 % ,CD44V6阳性表达率为 74 4% (6 7 90 ) ;PCNALI和CD44V6表达强度与胃癌淋巴结转移、浸润深度及TNM分期均呈显著正相关 (P <0 .0 5 ) ;PCNALI≥ 5 0 %或CD44V6强阳性表达的胃癌患者术后 1,3 ,5年生存率均显著降低 (P <0 .0 5 ) ;CD44V6阳性表达胃癌组织的PCNALI显著高于CD44V6阴性表达者 (P <0 .0 5 )。结论　PCNA和CD44V6表达与胃癌侵袭转移及预后显著相关 ;CD44V6的表达可能有助于胃癌增殖活性的增加     

唾液酸化路易斯-X抗原和CD44v6表达与胆管癌生物学行为的关系

目的　探讨唾液酸化路易斯 X(sialylLewis X ,SLeX)抗原和CD44v6表达与胆管癌生物学行为的关系。方法　用催化信号放大 (catalyzedsignalamplification ,CSA)免疫组化方法 ,检测 43例胆管癌组织及 10例慢性胆管炎组织中SLeX抗原和CD44v6蛋白的表达 ,分析SLeX和CD44v6蛋白的表达与胆管癌临床病理特征的关系。结果　在胆管癌组织中 ,SLeX和CD44v6表达阳性率分别为 67.4%和 62 .8% ,显著高于对照组的 2 0 .0 % (P<0 .0 5)。SLeX和CD44v6表达阳性率与胆管癌的TNM分期、分化程度、淋巴结和脏器转移密切相关 (P<0 .0 5)。SLeX表达与CD44v6表达呈正相关 (r =0 .49,P<0 .0 0 1)。结论　检测SLeX和CD44v6的基因表达可作为评估胆管癌生物学行为和预后的参考指标     

PCNA、CD44v6在原发性肝细胞癌的表达及临床意义

目的探讨PCNA、CD44v6在肝细胞癌(HCC)组织的表达及其临床病理意义.方法采用PCNA、CD44v6单克隆抗体,对83例HCC标本进行免疫组化染色.结果PCNA、CD44v6在HCC的阳性率分别为87.95%和53.01%.PCNA在EdmondsonⅠ、Ⅱ、Ⅲ、Ⅳ级的阳性率分别为01).CD44v6在转移组的高表达率为00%,有显著性差异(P＜0.42.86%、89.47%一92.86%、139.29%.明显高于无转移组(10.91%,P＜0.01).CD44v6在包膜完整组和不完整组的阳性率分别为35.42%和77.14%,有显著性差异(P＜0.01).CD44v6阳性病人的生存期明显短于CD44v6阴性病人(P＜0.05).PCNA和CD44v6在HCC的表达呈正相关.结论PCNA、CD44v6有望成为预测HCC发生、发展、转移、预后的生物学指标.     

人胆管癌组织中CD44v6蛋白的表达与胆管癌的关系

目的　探讨胆管癌组织中CD44v6表达与肿瘤转移及预后的关系。方法　对 46例胆管癌石蜡组织标本重新切片 ,采用CD44v6鼠单克隆抗体进行免疫组化染色 (S P法 )。结果　CD44v6在胆管癌组织中阳性表达率为 6 3% ,其与肿瘤的大小、部位、病理类型、肿瘤的分化程度无关 ,而与肿瘤TNM分期、淋巴结转移、中位生存期相关。Ⅳb期CD44v6阳性表达率 (83% )较Ⅳa期(6 8% )、Ⅰ、Ⅱ期 (33% )高 (P =0 0 31) ;有淋巴结转移者CD44v6阳性表达率 (85 % )较无淋巴结转移者(5 3% )高 (P =0 0 35 ) ;Ⅰ、Ⅱ期、Ⅳa期、Ⅳb期患者的中位生存期分别为 2 4、14、6个月 ,有淋巴结转移、无淋巴结转移病人的中位生存期分别为 8、2 3个月。结论　CD44v6在胆管癌的转移中具有一定的作用 ,可作为临床预测胆管癌转移潜能及预后的生物学指标。     

胃癌中CD44v6、P53和nm23H1基因蛋白表达及其意义

目的　探讨CD4 4v6、P5 3和nm2 3H1基因蛋白表达与胃癌临床病理学行为和患者预后的关系。方法　应用免疫组化技术检测 12 0例胃癌组织中CD4 4v6、P5 3和nm2 3H1基因蛋白表达 ,并结合肿瘤的病理学行为和临床随访资料分析。结果　在胃癌组织中 ,CD4 4v6、P5 3和nm2 3H1表达阳性率分别为 81 7%、6 8 3%和 4 8 3%。CD4 4v6和P5 3高表达和nm2 3H1低表达均与胃癌浆膜浸润、淋巴结转移和患者预后呈正相关 (P <0 .0 5 )。结论　CD4 4v6、P5 3和nm2 3H1表达与胃癌转移和患者生存期密切相关 ,检测CD4 4v6、P5 3和nm2 3H1基因蛋白表达可作为判断胃癌预后的参考指标     

CD44v6与乳腺癌转移和预后的关系

目的　研究CD44v6表达与乳腺癌转移和预后的关系。　方法　用免疫组化方法对 78例乳腺癌石蜡标本及 37例乳腺癌新鲜标本的CD44v6蛋白的表达水平进行了检测 ;RT PCR方法对 37例乳腺癌新鲜标本的CD44v6mRNA表达水平进行了检测。并对患者CD44v6的表达水平、肿瘤大小、腋淋巴结转移状况、TNM分期、组织学分级与预后间的关系进行了分析 ,同时比较 2种方法的敏感性。　结果　乳腺癌患者的CD44v6表达水平与原发肿瘤大小、腋淋巴结转移状况、TNM分期明显相关 ,是影响患者术后 5年生存率的重要因素。乳腺癌新鲜标本中CD44v6mRNA和蛋白的阳性表达率分别是 70 3%和 5 9 5 % ,两者差异无显著性意义 (P >0 0 5 )。　结论　乳腺癌患者的CD44v6的表达水平与癌细胞的转移和患者的预后相关 ;免疫组化和RT -PCR 2种方法 ,在检测CD44v6的敏感性方面差异无显著性。     

Immunohistochemical expression of CD44s in renal cell carcinoma lacks independent prognostic significance

Purpose: To analyze the immunohistochemical expression of the standard isoform of CD44 (CD44s) adhesion molecule in clear cell renal cell carcinoma (CCRCC) and its impact on clinical outcomes. Materials and Methods: Ninety-nine consecutive patients treated surgically for RCC between 1992 and 2009 were selected. A single pathologist reviewed all cases to effect a uniform reclassification and determine the most representative tumor areas for construction of a tissue microarray. The same pathologist, who was blinded to the outcome of the cases, semi-quantitatively scored the staining intensity of CD44s in all specimens. The counting was done using the H-Score algorithm. Results: Of the 99 immunostained RCC specimens, 57(57.7 %) showed low expression, and 42(42.4 %) showed high expression levels of CD44s. The expression of CD44s was directly associated with tumor size (p = 0.03), clinical stage (p = 0.02) and Fuhrman grade (p = 0.02). Disease specifi c survival (DSS) rates for patients whose specimens expressed low and high levels of CD44s was 88.1 % and 67.5 %, respectively (p = 0.009). Progression free survival (PFS) rates in patients with low and high expression of CD44s were 78.8 % and 61.7 %, respectively (p = 0.05). Classical features such as the presence of metastasis and clinical stage remained isolated predictors of survival. Conclusions: Immunohistochemical expression of CD44s was associated with important clinical variables such as stage and Fuhrman grade. However, it was not an independent predictor of survival. Therefore, we believe it has a limited role as a prognostic marker in patients with CCRCC.     

PCNA和CD44v6在皮肤鳞状细胞癌和基底细胞癌中表达的研究

目的：探讨增殖细胞核抗原PCNA、细胞粘附因子CD44v6在皮肤鳞状细胞癌（Squamous cell carcinoma,SCC）和基底细胞癌（Basal cell carcinoma,BCC）中表达的意义及相关性。方法：采用免疫组织化学法对82例石蜡包埋组织标本进行检测和统计分析。结果：①PCNA在皮肤SCC中阳性率（90.5%）显著高于皮肤BCC组（52%）和正常皮肤组（13.3%）,CD44v6在正常皮肤中的阳性率（100%）显著高于皮肤SCC组（66.7%）和皮肤BCC组（20%）;②PCNA的高表达率与皮肤SCC的分化程度呈负相关,CD44v6的高表达率与皮肤SCC的分化程度呈正相关;③PCNA和CD44v6在皮肤SCC和BCC中表达无明显相关。结论：CD44v6和PCNA与皮肤BCC和SCC的发生、分化密切相关,可作为研究和判断皮肤SCC和BCC生物学行为和预后独立的重要指标。     

Analysis of CD44 isoform v10 expression and its prognostic value in renal cell carcinoma

OBJECTIVE: To examine the expression of CD44 isoform v10 (CD44v10) in patients with renal cell carcinoma (RCC), analyse its role in RCC and its relationship with conventional clinical-histopathological experience. Materials and methods Sixty-four RCC specimens and five metastatic specimens were analysed immunohistochemically using a CD44v10 specific antibody. The expression of CD44v10 was compared with the histological grade and clinical or pathological stage of the tumours. RESULTS: Of the 64 primary tumour specimens, 22 (34%) expressed CD44v10 protein; all of these positive specimens were clear-cell and mixed-cell RCC. Staining was also positive in four of five metastatic specimens and negative in all four cases of granular cell carcinoma. CD44v10 expression was significantly correlated with the histological grade (P<0.0001), clinical stage (P = 0.0050) and pathological stage (P = 0.0143) of the tumours. The prognosis for patients with clear-cell RCC who were CD44v10-positive was worse than for patients who were CD44v10-negative (P<0.0001). In subgroups with different tumour stage (< or =pT2 or > or =pT3), the prognosis for patients with positive CD44v10 expression was also worse than for those with no expression (P<0.05). CONCLUSION: The expression of CD44v10 correlated significantly with histological grade, clinical and pathological stage, and with survival in patients with clear-cell RCC. CD44v10 protein may play a role in the progression of clear-cell and mixed-cell RCC, and thus the analysis of CD44v10 expression may provide useful prognostic information.     

肿瘤干细胞表面标记物CD44在胃癌中的表达及其意义

目的探讨肿瘤干细胞表面标记物CD44在胃癌中的表达及其意义。方法收集福建医科大学附属协和医院胃外科2006年12月至2007年12月间行根治性手术切除并经病理确诊的156例胃腺癌组织标本及对应的癌旁正常组织标本,采用免疫组织化学方法检测CD44家族成员CD44s、CD44v5和CD44v6蛋白的表达情况,并分析其与胃癌患者临床病理特征及预后的关系。结果CD44s在胃癌和癌旁组织中的表达率为50．0％（78／156）和40.3％（63／156）,差异无统计学意义（P〉0．05）。CD44v5和CD44v6在胃癌中的表达率分别为49．3％（77／156）和63．4％（99／156）,明显高于癌旁组织中的7．6％（12／156）和0（均P〈0．05）。3种蛋白在胃癌组织中的表达两两之间无明显相关性（均P〉0．05）。在胃癌组织中,CD44s的表达与胃癌浸润深度、淋巴结转移和TNM分期相关：CD44v5的表达仅与胃癌浸润深度相关;CD44v6的表达与浸润深度、淋巴结转移、TNM分期和Lauren分型相关。CD44s、CD44v5及CD44v6表达阳性组和阴性组的5年生存率分别为35．8％和52．5％（P〈0．05）、38．9％和49．3％（P〉0．05）及26．2％和75．4％（P（0．05）,仅CD44v6表达是胃癌的独立预后因素（RR=I．931,95％CI：1．183—3．152）。结论CD44参与胃癌浸润和淋巴结转移过程,CD44可能成为胃癌预后预测指标之一。     

不同肾癌亚型组织中c-kit与增殖细胞核抗原的表达及意义

目的 探讨不同亚型肾癌组织中c-kit及增殖细胞核抗原(PCNA)的表达及临床意义.方法 采用免疫组化SP法测定137例透明细胞癌、82例乳头状癌、51例嫌色细胞癌标本中c-kit蛋白和PCNA的表达情况. 结果 嫌色细胞癌中c-kit强阳性表达率为94.1%(48/51),明显高于透明细胞癌的16.1%(22/137)及乳头状癌的28.1%(23/82),差异有统计学意义(P=0.001).c-kit强阳性表达仅与嫌色细胞癌分期有关(P=0.038);在透明细胞癌和乳头状癌中PCNA表达与分级关系密切(P=0.043,P=0.011),而与嫌色细胞癌分级无关. 结论 嫌色细胞癌中c-kit表达率明显高于其他肾癌亚型,且与肿瘤局部进展关系密切.不同亚型间c-kit表达差异有助于肾癌的临床鉴别诊断和指导晚期肾癌靶向治疗药物的选择.     

大肠癌虚证实证与CD44v6、PCNA表达的相关性研究

目的:通过检测细胞粘附分子(CD44v6)及增殖细胞核抗原(PCNA)在大肠癌不同中医证型中的表达,探讨CD44v6、PCNA与虚实证型的关系。方法:采用前瞻性组间对照的研究方法,筛选符合标准的大肠癌患者51例和大肠息肉患者17例,术前认真辨证,术后标本免疫组化检测各种证型组织中CD44v6及PCNA的表达。结果:息肉组织中CD44v6无表达或呈弱表达,大肠癌组织中CD44v6表达明显增强。大肠癌虚证与实证中有淋巴结转移或全身多处转移的患者,CD44v6的表达有显著差异性(P<0.05),实证占85.7%,虚证占46.2%,而PCNA的表达无差异性(P>0.05)。结论:CD44v6、PCNA在大肠癌中的表达具有较高的特异性。CD44v6作为细胞黏附蛋白分子,同肠癌的发生与发展可能有关,对大肠癌预后的判断具有重要的参考价值。PCNA在大肠癌进展期表达具有特征性意义。大肠癌实证中有淋巴结转移或全身多处转移的患者CD44v6的表达明显高于虚证中的表达,提示CD44v6及转移倾向与邪气的盛衰相关。     

Carbonic anhydrase IX as a specific biomarker for clear cell renal cell carcinoma: comparative study of Western blot and immunohistochemistry and implications for diagnosis

Abstract Objective. This study aimed to evaluate the usefulness of carbonic anhydrase IX (CA-IX) expression in clear cell renal cell carcinoma (CCRCC) using two different techniques to detect protein expression. Material and methods. An experimental, cross-sectional, analytical study was conducted to analyse proteins in renal tumour and healthy tissue specimens from 38 consecutive patients who underwent nephrectomy for renal cancer. CA-IX protein expression was measured by immunohistochemistry and Western blot analysis and quantified. Statistical analysis was performed with the positive and negative specific agreements and kappa coefficient. The sensitivity and specificity of both techniques were assessed. Statistical tests were conducted to analyse the association between CA-IX expression quantitation and normal prognosis factors (TNM stage and Fuhrman nuclear grade), only in CCRCC. Results. The mean patient age was 65 years, 78.9% of patients were men and 57.9% of tumours were CCRCC. CA-IX protein expression was positive in 63.2% of tumours by immunohistochemistry and in 60.5% by Western blot. Both techniques detected CA-IX expression only in CCRCC and unclassifiable tumours. High concordance indices were observed for CCRCC diagnosis. Western blot and immunohistochemistry had a sensitivity of 95.5% and 100%, respectively; the specificity was 100% in both techniques. CA-IX expression quantitation did not correlate with tumour stage or Fuhrman nuclear grade. Conclusions. Immunochemistry and Western blot techniques can be used to detect abnormal CA-IX protein expression in CCRCC and to support morphology-based diagnostic techniques.     

胃癌中RhoC和CD44v6及ICAM-1的表达及其相关性的初步研究

目的探讨RhoC、CD44v6和ICAM-1在胃癌中的表达及其相关性。方法应用免疫组织化学SABC法检测RhoC、CD44v6和ICAM-1在40例胃癌组织的表达情况,结合其临床病理学资料,分析它们之间的相关性。结果RhoC、CD44v6和ICAM-1的表达与肿瘤细胞分化、浸润深度无关(P>0.05),但与淋巴结转移、PTNM分期具有相关性(P<0.05)。RhoC与CD44v6和ICAM-1的表达存在相关性(分别为r=0.355,P=0.006;r=0.354,P=0.003)。当RhoC为阳性,CD44v6和ICAM-1两者之一为阳性时,对预测胃癌淋巴结转移的灵敏性和特异性分别为93.8%和62.5%。结论RhoC、CD44v6和ICAM-1的阳性表达预示胃癌具有较强的侵袭转移能力,可作为预测胃癌转移潜能的生物学指标。联合检验以上3种指标有望成为预测胃癌淋巴结转移的又一种有价值的手段。     

粘附分子CD44v6和E—cadherin的表达与甲状腺乳头状癌侵袭转移的关系

目的 探讨粘附分子CD44v6和E－cadherin表达与甲状腺乳头状瘤（PTC）侵袭转移的关系。 方法 应用S－P免疫组织化学方法检测58例甲状腺乳头状癌组织中CD44v6和E－cadherin的表达。结果 甲状腺乳头状癌组织中CD44v6和E－cadherin表达阳性率分别为72．4％和41．4％;CD44v6表达阳性率与PTC的侵袭和转移呈正相关（P＜0．05）,而E-cadherin表达阳性率与PTC的侵袭和转移呈负相关（P＜0．01）,且两种粘附分子在PTC中的阳性表达呈负相关性（P＜0．05）。结论 粘附分子表达与PTC侵袭和转移密切相关,检测CD44v6和E－cadherin的表达可作为判断甲状腺乳头状癌预后的参考指标。